News | September 18, 2006

Cypher and Taxus Face Off in Barcelona Arena

Plus, underuse of aspirin after stent is “a travesty” says Mayo doctor

Cardiologists were urged to halt the "epidemic of madness" behind drug-eluting stent (DES) overuse, during an address by Salim Yusuf, M.D., McMaster University, Hamilton, Ontario, at the World Congress of Cardiology in Barcelona.

Meanwhile, other physicians focused on the efficacy of clopidogrel in preventing stent thrombosis during discussions of two meta- analyses and registry study, all of which showed an increase in mortality with DES, according to a report from

While no clopidogrel data was provided in the meta-analysis presented by Dr Edoardo Camenzind (University Hospital Geneva, Switzerland), death and MI were strikingly higher in the patients on Cypher stents as compared with bare-metal stents, while there was no significant differences in these end points in the Taxus-treated patients compared with bare-metal stents.

Sigmund Silber, M.D., Dr Müller Hospital, Munich, Germany, said the disparity between Cypher and Taxus was attributable to the duration of clopidogrel – only three months in the Cypher studies compared to six months in the Taxus trials.

Another opinion was that meta-analysis is insufficient and just an impetus to do more randomized trials.

Less publicized portions of current studies, according to heartwire’s interview with Raymond Gibbons, M.D., Mayo Clinic, Rochester, MN, include the fact that 26 percent of patients in the Rotterdam/Bern registry study were not even on aspirin after undergoing stent implantation. "That is a clear violation of international guidelines," Gibbons stated. "That's what the story should be. . . . An unacceptable number of patients with known CAD are not taking aspirin. This is the single most cost-effective thing that we do in medicine, and it's a travesty that we're not doing better."

For more information, visit

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init